Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Conditions
Interventions
Low Dose GC4419: 30mg/day
High Dose GC4419: 90mg/day
+3 more
Locations
64
United States
University of Arizona Cancer Center at Dignity Health St. Joseph's
Phoenix, Arizona, United States
University of Arizona
Tucson, Arizona, United States
Fowler Family Center for Cancer Care
Jonesboro, Arkansas, United States
University of Arkansas for Medical Sciences- Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas, United States
VA Long Beach Healthcare System
Long Beach, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Start Date
October 12, 2015
Primary Completion Date
September 18, 2017
Completion Date
August 29, 2019
Last Updated
September 20, 2021
Lead Sponsor
Galera Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions